News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Carrington Laboratories, Inc. (CARN) Names Maria Eaton Vice President, Support Services

1/17/2008 6:58:24 AM

IRVING, Texas, Jan. 17 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. today announced the promotion of Maria Eaton to vice president, Support Services. In this capacity, she will oversee the Company's purchasing, planning and production, document control, and transfer of technology from Research and Development through production of finished product.

Ms. Eaton joined Carrington in 1997 as executive assistant and special assistant to the CEO. She has since assumed numerous operational responsibilities, the most recent of which was director, Support Services.

Carlton Turner, CEO of Carrington said, "Ms. Eaton's promotion to vice president is well deserved. She has demonstrated extraordinary ability in managing complex operations. She also understands manufacturing and regulatory details required to meet FDA and ISO requirements for each of the product groups manufactured by Carrington. Integrating these diverse needs into a system for efficiency in purchasing, planning, and production has greatly reduced our inventory."

Prior to joining Carrington, Ms. Eaton attended the University of North Texas and was previously employed in the healthcare industry.

About Carrington

Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's DelSite Biotechnologies subsidiary is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit

Certain statements in this release concerning Carrington may be forward- looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission.

CONTACT: Carlton E. Turner, Chief Executive Officer of Carrington
Laboratories, Inc., +1-972-518-1300

Web site:

Read at

comments powered by Disqus